Evidence map›Paper›PMID 31186261›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2019

miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study.

Loki Natarajan, Minya Pu, Sherri R Davies, Tammi L Vickery, Sandahl H Nelson, Emily Pittman, Barbara A Parker, Matthew J Ellis, Shirley W Flatt, Elaine R Mardis and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Loki NatarajanDepartment of Family Medicine and Public Health, University of California, San Diego, La Jolla, California. lnatarajan@ucsd.edu.
Minya PuMoores Cancer Center, University of California, San Diego, La Jolla, California.
Sherri R DaviesDepartment of Medicine, Washington University in St. Louis, St. Louis, Missouri.ORCID 0000-0002-7141-8354
Tammi L VickeryMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri.
Sandahl H NelsonDepartment of Family Medicine and Public Health, University of California, San Diego, La Jolla, California.
Emily PittmanMoores Cancer Center, University of California, San Diego, La Jolla, California.
Barbara A ParkerMoores Cancer Center, University of California, San Diego, La Jolla, California.ORCID 0000-0003-0499-1289
Matthew J EllisBaylor College of Medicine, Lester and Sue Smith Breast Center, Houston, Texas.ORCID 0000-0002-8467-8534
Shirley W FlattMoores Cancer Center, University of California, San Diego, La Jolla, California.
Elaine R MardisInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio.
Catherine R MarinacDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
John P PierceDepartment of Family Medicine and Public Health, University of California, San Diego, La Jolla, California.
Karen MesserDepartment of Family Medicine and Public Health, University of California, San Diego, La Jolla, California.

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Genomic, clinical and behavioral signature of long-term breast cancer survivalR01CA166293 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESSER, KAREN, NATARAJAN, LOKI · 2013 to 2016
$1.6M
Obesity, Molecular Biomarkers, and Multiple Myeloma PrognosisF32CA220859 · NCI · DANA-FARBER CANCER INST · PI MARINAC, CATHERINE · 2018 to 2019
$94k
NCI NIH HHS F32 CA220859NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA166293
6 · The paper itself

Abstract

backgroundThere is substantial variation in breast cancer survival rates, even among patients with similar clinical and genomic profiles. New biomarkers are needed to improve risk stratification and inform treatment options. Our aim was to identify novel miRNAs associated with breast cancer survival and quantify their prognostic value after adjusting for established clinical factors and genomic markers.

methodsUsing the Women's Healthy Eating and Living (WHEL) breast cancer cohort with >15 years of follow-up and archived tumor specimens, we assayed PAM50 mRNAs and 25 miRNAs using the Nanostring nCounter platform.

resultsWe obtained high-quality reads on 1,253 samples (75% of available specimens) and used an existing research-use algorithm to ascertain PAM50 subtypes and risk scores (ROR-PT). We identified miRNAs significantly associated with breast cancer outcomes and then tested these in independent TCGA samples. miRNAs that were also prognostic in TCGA samples were further evaluated in multiple regression Cox models. We also used penalized regression for unbiased discovery.

conclusionsTwo miRNAs, 210 and 29c, were associated with breast cancer outcomes in the WHEL and TCGA studies and further improved risk stratification within PAM50 risk groups: 10-year survival was 62% in the node-negative high miR-210-high ROR-PT group versus 75% in the low miR-210- high ROR-PT group. Similar results were obtained for miR-29c. We identified three additional miRNAs, 187-3p, 143-3p, and 205-5p, via penalized regression. IMPACT: Our findings suggest that miRNAs might be prognostic for long-term breast cancer survival and might improve risk stratification. Further research to incorporate miRNAs into existing clinicogenomic signatures is needed.

Indexed as

AdolescentAdultAgedBreast NeoplasmsFemaleHumansMiddle AgedSurvival AnalysisYoung Adult

Identifiers

PMID31186261
PMCPMC6726562

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.